Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report

Oncotarget

Volumn 8, Issue 11, 2017, Pages 18609-18614

  Li, Lin ^a   Wang, Hui ^a   Li, Chao ^a   Wang, Zheng ^a   Zhang, Ping ^a   Yan, Xu ^a  

^a BEIJING HOSPITAL   (China)

Author keywords

Acquired resistance; AZD9291; EGFR TKI; NSCLC; Transformation

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; NEDAPLATIN; OSIMERTINIB; PEMETREXED; ACRYLAMIDE DERIVATIVE; ANILINE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ADULT; ADVANCED CANCER; ARTICLE; BIOTRANSFORMATION; CANCER GROWTH; CANCER RESISTANCE; CANCER STAGING; CASE REPORT; CELL TRANSFORMATION; DRUG EFFICACY; DRUG SAFETY; EXON; FEMALE; GENE DELETION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER METASTASIS; LUNG ADENOCARCINOMA; MIDDLE AGED; SMALL CELL CARCINOMA; TREATMENT RESPONSE; TUMOR BIOPSY; DRUG RESISTANCE; GENETICS; PATHOLOGY; SMALL CELL LUNG CANCER;

ACRYLAMIDES; ANILINE COMPOUNDS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; SMALL CELL LUNG CARCINOMA;

EID: 85015205318     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.14506     Document Type: Article

References (14)

1. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011; 3: 75ra26.
2. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013; 19: 2240-7.
3. Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015; 372: 1689-99.
4. Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in nonsmall cell lung cancer harboring EGFR T790M. Nat Med. 2015; 21: 560-2.
5. Yu HA, Tian SK, Drilon AE, Borsu L, Riely GJ, Arcila ME, Ladanyi M. Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. JAMA Oncol. 2015; 1: 982-4.
6. Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, Sequist LV, Engelman JA. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. Clin Cancer Res. 2015; 21: 3924-33.
7. Ou SH, Agarwal N, Ali SM. High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression. Lung Cancer. 2016; 98: 59-61.
8. Kim TM, Song A, Kim DW, Kim S, Ahn YO, Keam B, Jeon YK, Lee SH, Chung DH, Heo DS. Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor. J Thorac Oncol. 2015; 10: 1736-44.
9. Ham JS, Kim S, Kim HK, Byeon S, Sun JM, Lee SH, Ahn JS, Park K, Choi YL, Han J, Park W, Ahn MJ. Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment. J Thorac Oncol. 2016; 11: e1-4.
10. Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to smallcell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015; 16: e165-72.
11. Zhang Y, Li XY, Tang Y, Xu Y, Guo WH, Li YC, Liu XK, Huang CY, Wang YS, Wei YQ. Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFRtyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma? Lung Cancer. 2013; 81: 302-5.
12. Watanabe S, Sone T, Matsui T, Yamamura K, Tani M, Okazaki A, Kurokawa K, Tambo Y, Takato H, Ohkura N, Waseda Y, Katayama N, Kasahara K. Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma. Lung Cancer. 2013; 82: 370-2.
13. Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, Yang JC, Barrett JC, Janne PA. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016; 34: 3375-82.
14. Dowlati A, Lipka MB, McColl K, Dabir S, Behtaj M, Kresak A, Miron A, Yang M, Sharma N, Fu P, Wildey G. Clinical correlation of extensive-stage small-cell lung cancer genomics. Ann Oncol. 2016; 27: 642-7.